Neuro-SysMed-seminar 22. april 2026
Velkommen til Neuro-SysMed sine månadlege seminar! Bli med i auditoriet i Armauer Hansens Hus kl. 11:30–13:00 (lunsj fra 11:30–12:00). Emnet denne gongen blir presentert frå Neuro-SysMeds ALS-node.
Hovedinnhold
Forelesar
Ole-Bjørn Tysnes og Mari Klauset Holtom frå Neuro-SysMed sin ALS-node (ekstern lenke).
Emne
"Challenges in running a multicentre RCT. The NO-ALS study experience." (Undervisingsspråk er engelsk.)
Påmelding
Påmelding gjerast gjennom denne koplinga (ekstern lenke (ekstern lenke)) (ekstern lenke). Fristen er 20. april kl. 11.00 dersom du vil vere med på lunsjen. Heilt fram til seminaret startar dersom ikkje.
Tid og stad
Stad: Auditoriet i Armauer Hansens Hus
Når: 22. april 2026 kl. 11:30 - 13:00 (lunsj 11:30 - 12:00).
Samandrag
There are currently no neuroprotective treatments for Amyotrophic lateral sclerosis (ALS) with a significant impact on disease progression. Previous research by the PD Node and others has nominated NAD-replenishment therapy as a promising neuroprotective strategy against neurodegeneration. Moreover, prior to the NO-ALS study, a published small trial using a combination of the NAD-precursor nicotinamide riboside (NR) and sirtuin booster pterostilbene, showed encouraging findings in ALS. To test the potential of this strategy as a neuroprotective therapy for ALS, Neuro-SysMed Centre for Clinical Treatment Research initiated the NO-ALS trial, a phase-II, multicentre, double-blinded randomized trial of oral NR and pterostilbene inn early ALS. At this seminar, Professor Ole-Bjørn Tysnes and Study Nurse Mari Klauset Holtom from Neuro-SysMed's ALS node will discuss experiences from the NO-ALS trial, and discuss challenges in running a multicentre randomized clinical trial.